(Q35917315)

11 August 2017

1 reference

title

Peginterferon-alpha(2b) and ribavirin (English)

1 reference

11 August 2017

1 reference

Joseph Ahn

1

1 reference

11 August 2017

Steven Flamm

series ordinal

2

1 reference

11 August 2017

publication date

1 February 2004

1 reference

Expert Review of Anti-infective Therapy

11 August 2017

published in

1 reference

11 August 2017

volume

2

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

17-25

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Population pharmacokinetic analysis of pegylated interferon alfa-2b and interferon alfa-2b in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Pegylated interferons for the treatment of chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Structural and biologic characterization of pegylated recombinant IFN-alpha2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Mechanisms of action of interferons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Possible mechanisms of action and reasons for failure of antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Interferons and their actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.2.1.17

21 January 2018

Identifiers

DOI

10.1586/14787210.2.1.17

1 reference

11 August 2017

1 reference